» Articles » PMID: 1730874

IL-10, T Lymphocyte Inhibitor of Human Blood Cell Production of IL-1 and Tumor Necrosis Factor

Overview
Journal J Immunol
Date 1992 Feb 1
PMID 1730874
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

We have identified and purified a factor that inhibits the production of IL-1 beta and TNF by stimulated human mononuclear cells. The activity is produced by the T cell lines Hut-78 and Mo constitutively under serum-free conditions. Crude conditioned media have titers of up to 100 U/ml (one unit defined as the reciprocal of the dilution producing 50% inhibition). The activity resides mainly in a single size peak of 30 to 35 kDa and an isoelectric point around 8. Other cytokines in this size range that have been reported to be inhibitory for IL-1 and TNF production include TGF-beta, IL-4, and IL-6; these factors were excluded by lack of detection, neutralizing antibody, and low activity compared with our factor. Another factor with these size and charge properties is IL-10, which inhibits T cell cytokine production. By polymerase chain reaction analysis, Mo and HuT-78 lines contain IL-10 transcripts whereas JURKAT is negative; this correlates with inhibitor bioactivity from the three lines. Use of mAb specifically showed the inhibitor to be IL-10.

Citing Articles

T-Cell Subtypes and Immune Signatures in Cutaneous Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy.

Absmaier-Kijak M, Iuliano C, Kaesler S, Biedermann T, Posch C, Brockow K Cancers (Basel). 2024; 16(6).

PMID: 38539560 PMC: 10969757. DOI: 10.3390/cancers16061226.


Flagellin-Induced Immune Response in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Yuecel G, Zhou X, Terkatz L, Wendel A, Reinhardt J, El-Battrawy I Int J Mol Sci. 2023; 24(18).

PMID: 37762236 PMC: 10531389. DOI: 10.3390/ijms241813933.


Next-generation nanomaterials: advancing ocular anti-inflammatory drug therapy.

Wei J, Mu J, Tang Y, Qin D, Duan J, Wu A J Nanobiotechnology. 2023; 21(1):282.

PMID: 37598148 PMC: 10440041. DOI: 10.1186/s12951-023-01974-4.


Dysregulated inflammasome activity in intestinal inflammation - Insights from patients with very early onset IBD.

Illig D, Kotlarz D Front Immunol. 2022; 13:1027289.

PMID: 36524121 PMC: 9744759. DOI: 10.3389/fimmu.2022.1027289.


Topical Administration of SLN-Based Gene Therapy for the Treatment of Corneal Inflammation by De Novo IL-10 Production.

Vicente-Pascual M, Gomez-Aguado I, Rodriguez-Castejon J, Rodriguez-Gascon A, Muntoni E, Battaglia L Pharmaceutics. 2020; 12(6).

PMID: 32586018 PMC: 7355708. DOI: 10.3390/pharmaceutics12060584.